SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer

Guy A van Hazel; Volker Heinemann; Navesh K Sharma; Michael PN Findlay; Jens Ricke; Marc Peeters; David Perez; Bridget A Robinson; Andrew H Strickland; Tom Ferguson; Javier Rodriguez; Hendrik Kroening; Ido Wolf; Vinod Ganju; Euan Walpole; Eveline Boucher; Thomas Tichler; Einat Shacham-Shmueli; Alex Powell; Paul Eliadis; Richard Isaacs; David Price; Fred Moeslein; Julien Taieb; Geoff Bower; Val Gebski; Mark Van Buskirk; David N Cade; Kenneth Thurston; Peter Gibbs

Journal article

SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer

Guy A van Hazel, Volker Heinemann, Navesh K Sharma, Michael PN Findlay, Jens Ricke, Marc Peeters, David Perez, Bridget A Robinson, Andrew H Strickland, Tom Ferguson, Javier Rodriguez, Hendrik Kroening, Ido Wolf, Vinod Ganju, Euan Walpole, Eveline Boucher, Thomas Tichler, Einat Shacham-Shmueli, Alex Powell, Paul Eliadis Show all

Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2016

DOI: 10.1200/JCO.2015.66.1181

University of Melbourne Researchers

Peter Gibbs Author Surgery - Royal Melbourne Hospital

Grants

Funding Acknowledgements

We thank all investigators in the SIRFLOX Study Group, and in particular the principal investigators. We acknowledge the editorial assistance provided by Martin Gilmour of ESP Bioscience (Crowthorne, United Kingdom) funded by Sirtex, during the preparation of this article.